BDTX - Black Diamond Therapeutics, Inc.
2.7
-0.220 -8.148%
Share volume: 695,233
Last Updated: 04-28-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances:
0.20%
PREVIOUS CLOSE
CHG
CHG%
$2.92
-0.22
-0.08%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 05-09-2024 | 08-06-2024 | 11-05-2024 | 03-06-2025 | 05-12-2025 | 11-06-2025 | 03-16-2026 | |
| Total revenue | 0.000 | 0.000 | 0.000 | 0.000 | 70.000 M | 0.000 | 0.000 | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 0.000 | 0.000 | 0.000 | 0.000 | 70.000 M | 0.000 | 0.000 | |
| nan% | nan% | nan% | -100.00% | nan% | ||||
| Operating expenses | 20.246 M | 22.130 M | 18.130 M | 18.275 M | 15.470 M | 10.978 M | 10.262 M | |
| Selling general and admin | 6.701 M | 9.574 M | 5.216 M | 5.978 M | 4.964 M | 3.541 M | 3.966 M | |
| Research and development | 13.545 M | 12.556 M | 12.914 M | 12.297 M | 10.506 M | 7.437 M | 6.296 M | |
| Total expenses | 20.246 M | 22.130 M | 18.130 M | 18.275 M | 15.470 M | 10.978 M | 17.610 M | |
| 9.31% | -18.08% | 0.80% | -15.35% | -29.04% | 60.41% | |||
| Operating income | -20.246 M | -22.130 M | -18.130 M | -18.275 M | 54.530 M | -10.978 M | -17.610 M | |
| Ebit | -18.862 M | -20.373 M | -16.073 M | -16.550 M | 55.947 M | -9.662 M | -16.300 M | |
| Pretax income | -18.225 M | -19.909 M | -15.557 M | -15.985 M | 56.542 M | -8.498 M | -15.116 M | |
| 9.24% | -21.86% | 2.75% | -453.72% | -115.03% | 77.88% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | -18.225 M | -19.909 M | -15.557 M | -15.985 M | 56.542 M | -8.498 M | -15.116 M | |
| -9.24% | 21.86% | -2.75% | 453.72% | -115.03% | -77.88% |